Becton, Dickinson and Company (BDX) – Analysts’ Weekly Ratings Updates

Becton, Dickinson and Company (NYSE: BDX) has recently received a number of price target changes and ratings updates:

• 8/13/2026 – Becton, Dickinson and Company had its “buy” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Becton, Dickinson and Company had its price target raised by Royal Bank Of Canada from $180.00 to $190.00. They now have a “sector perform” rating on the stock.
• 8/7/2026 – Becton, Dickinson and Company had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 8/7/2026 – Becton, Dickinson and Company was given a new $195.00 price target by Stifel Nicolaus.
• 8/7/2026 – Becton, Dickinson and Company had its price target raised by Royal Bank Of Canada from $175.00 to $180.00. They now have a “sector perform” rating on the stock.
• 8/7/2026 – Becton, Dickinson and Company had its “hold” rating reaffirmed by Royal Bank Of Canada.
• 8/7/2026 – Becton, Dickinson and Company had its price target raised by Citigroup Inc. from $198.00 to $204.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Becton, Dickinson and Company had its price target raised by Piper Sandler from $161.00 to $175.00. They now have a “neutral” rating on the stock.
• 8/7/2026 – Becton, Dickinson and Company had its price target raised by Wells Fargo & Company from $161.00 to $170.00. They now have an “equal weight” rating on the stock.
• 8/6/2026 – Becton, Dickinson and Company had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $210.00 price target on the stock.
• 8/5/2026 – Becton, Dickinson and Company had its price target raised by TD Cowen from $163.00 to $182.00. They now have a “hold” rating on the stock.
• 7/28/2026 – Becton, Dickinson and Company is now covered by UBS Group AG. They set a “buy” rating and a $190.00 price target on the stock.
• 7/28/2026 – Becton, Dickinson and Company is now covered by UBS Group AG. They set a “buy” rating and a $190.00 price target on the stock.
• 7/6/2026 – Becton, Dickinson and Company was given a new $180.00 price target by Evercore Inc.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 in the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.